Expert: Alessandra Curioni-Fontecedro, University Hospital Zurich, Zurich, Switzerland

Questions:

1.What's the accurate definition of immunotherapy rechallenge?

2.When we could rechallenge with immunotherapy after failure of previous I.O based therapy ?

3.There is any biomarkers to guide us in I.O rechallenge?

4.Which type of I..O could be used after failure of previous I.O?

5.what is the current trials that investigate this type of therapy?

Expert: Nicholas Pavlidis, University of Ioannina, Ioannina, Greece

Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy

Expert: Sabrina Kahler Ribeiro Fontana, European Institute of Oncology, Milan, Italy

Expert: Nicola Fusco, University of Milan and IRCCS European Institute of Oncology, Milan, IT

Expert: Maggie Banys Paluchowski, University Hospital Schleswig-Holstein (UKSH), Lübeck, DE

Questions:

1-Why do we need localization techniques?

2-How to perform intraoperative ultrasound?

3-Can you comment on the available evidence on intraoperative ultrasound?

4-What can be potential problems of intraoperative ultrasound?

5-What about intraoperative ultrasound in palpable lesions?

Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy

Expert: Erick Figueiredo Saldanha, AC Camargo Cancer Center, Sao Paulo, Brazil

Expert

Ramon Andrade Bezerra de Mello, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil

Questions:

1-How to clinically approach metastatic gastric cancer in terms of molecular biomarkers?

2-What is the best sequence treatment for advanced gastric cancer?

3-How to approach the second line and beyond in advanced gastric cancer?

4-Perspectives of the ICI combinations for advanced gastric cancer?

Expert: Ilaria Colombo, Oncology Institute of Southern Switzerland, Bellinzona, CH

Questions:

1-Which is the mechanism of action of PARP inhibitors and why this is relevant in ovarian cancer?

2-How can we measure the homologous recombination deficiency?

3-Which is the current evidence for the use of maintenance PARP inhibitors in recurrent epithelial ovarian cancer?

4-Can you tell us which are the results of phase 3 trials that have investigated PARP inhibitors in front line treatment of epithelial ovarian cancer?

5-Which are the main toxicities of PARP inhibitors?